Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. | Available online http arthritis-research.eom content 8 4 R112 Research article Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease attrition and long-term evolution of disease activity Bert Vander Cruyssen1 Stijn Van Looy2 Bart Wyns2 Rene Westhovens3 Patrick Durez4 Filip Van den Bosch1 Herman Mielants1 Luc De Clerck5 Ann Peretz6 Michel Malaise7 Leon Verbruggen8 Nathan Vastesaeger9 Anja Geldhof10 Luc Boullart2 and Filip De Keyser1 Open Access Department of Rheumatology Ghent University Hospital B-9000 Gent Belgium department of Electrical Energy Systems and Automation Ghent University Gent Belgium department of Rheumatology University Hospitals K.U. Leuven Leuven Belgium department of Rheumatology Cliniques Universitaires Saint-Luc Brussels Belgium department of Rheumatology University Hospital Antwerp Antwerp Belgium department of Rheumatology University Hospital Brugmann Brussels Belgium department of Rheumatology University Hospital Liège Liège Belgium department of Rheumatology AZ Vrije Universiteit Brussel Brussels Belgium department of Medical Affairs Schering-Plough Brussels Belgium 10Department of Medical Affairs Centocor BV Leiden the Netherlands Corresponding author Bert Vander Cruyssen Bert.VanderCruyssen@Ugent.be Received 27 Mar 2006 Revisions requested 11 May 2006 Revisions received 12 Jun 2006 Accepted 29 Jun 2006 Published 17 Jul 2006 Arthritis Research Therapy 2006 8 R112 doi 10.1186 ar2001 This article is online at http arthritis-research.com content 8 4 R112 2006 Vander Cruyssen et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis .